

February 06, 2025

To, BSE Limited 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 500120

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra — Kurla Complex, Bandra (E) Mumbai — 400 051 Symbol: DIAMINESQ

Sub: Disclosure of Regulation 32(1) of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on September 30, 2024.

Dear Sir/Ma'am,

Pursuant to the Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statement of deviation or variation of fund raised through preferential issue under Regulation 32(1) of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on December 31, 2024, is enclosed herewith.

Kindly take the above mentioned information on records.

Thanking You,

Yours Faithfully, For Diamines and Chemicals Limited

Hemaxi Pawar Company Secretary Membership No.: A52581 Encl: As above

Diamines and Chemicals Limited (CIN No.L24110GJ1976PLC002905) Plot No. 13 P.C.C. Area, P.O. Petrochemicals, Dist. Vadodara 391346, Gujarat (India). T: +91 265 3534200, F: +91 265 2230218 E: info@dacl.co.in, W:dacl.co.in



Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Diamines And Chemicals Limited					
Mode of Fund Raising						
	Public Issues / Rights Issues / Preferential Issues / QIP / Others					
Date of Raising Funds	October 01, 2024 (Date of Allotment)					
Amount Raised	₹ 50.58 Cr (100% of issue) *					
Report filed for Quarter ended	December 31, 2024					
Monitoring Agency	applicable / not applicable					
Monitoring Agency Name, if	NA					
applicable						
Is there a Deviation / Variation	Yes / No					
in use of funds raised						
If yes, whether the same is	NA					
pursuant to change in terms of						
a contract or objects, which was						
approved by the shareholders						
If Yes, Date of shareholder	NA					
Approval						
Explanation for the Deviation /	NA					
Variation						
Comments of the Audit	None					
Committee after review						
Comments of the auditors, if	None					
any						
Objects for which funds have						
been raised and where there						
has been a deviation, in the						
following table			-		-	
Original Object	Modified	Original	Modified	Funds	Amount of	Remarks
	Object, if	Allocation	allocation,	Utilised	Deviation/Vari	
	any	(Rs in	if any	(Rs in	ation for the	
		Crores)		Crores)	quarter	
					according to	
					applicable	
					object	
capital expenditures, working	NA	50.58	NA	-	-	12.51 crores
capital requirements,						received (i.e. 25% of
acquisition, investment in						the issue i.e. 906390
technology and for general						convertible
corporate purpose						warrants @ Rs. 552
						per warrant)

Deviation or variation means:

(a) Deviation in the object or purposes for which the funds has been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in the terms of contract referred to in the funds raising documents i.e. prospectus, letter of offer, etc

*Note: The Company had received In-Principle approval on September 19, 2024 for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Board, in its meeting held on October 01, 2024, had allotted 906390 convertible warrants on receipt of subscription money Rs. 12.51 crores i.e. 25% of the total Issue, on preferential basis to the investors.

Plot No. 13 P.C.C. Area, P.O. Petrochemicals, Dist. Vadodara 391346, Gujarat (India). T: +91 265 3534200, F: +91 265 2230218 E: info@dacl.co.in, W:dacl.co.in